JP2006514823A - 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 - Google Patents

子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 Download PDF

Info

Publication number
JP2006514823A
JP2006514823A JP2004529772A JP2004529772A JP2006514823A JP 2006514823 A JP2006514823 A JP 2006514823A JP 2004529772 A JP2004529772 A JP 2004529772A JP 2004529772 A JP2004529772 A JP 2004529772A JP 2006514823 A JP2006514823 A JP 2006514823A
Authority
JP
Japan
Prior art keywords
marker
expression
patient
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004529772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514823A5 (enExample
Inventor
ジョン， イー． モナハン，
シューメイ ツァオ，
ヤン チェン，
カレン グラット，
シュブハンギ カマトカル，
Original Assignee
ミレニアム ファーマスーティカルズ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミレニアム ファーマスーティカルズ インク filed Critical ミレニアム ファーマスーティカルズ インク
Publication of JP2006514823A publication Critical patent/JP2006514823A/ja
Publication of JP2006514823A5 publication Critical patent/JP2006514823A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2004529772A 2002-08-20 2003-08-20 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 Pending JP2006514823A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40477002P 2002-08-20 2002-08-20
PCT/US2003/026184 WO2004018999A2 (en) 2002-08-20 2003-08-20 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010181748A Division JP2011036247A (ja) 2002-08-20 2010-08-16 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法

Publications (2)

Publication Number Publication Date
JP2006514823A true JP2006514823A (ja) 2006-05-18
JP2006514823A5 JP2006514823A5 (enExample) 2010-02-18

Family

ID=31946760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004529772A Pending JP2006514823A (ja) 2002-08-20 2003-08-20 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
JP2010181748A Pending JP2011036247A (ja) 2002-08-20 2010-08-16 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010181748A Pending JP2011036247A (ja) 2002-08-20 2010-08-16 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法

Country Status (9)

Country Link
US (3) US7361511B2 (enExample)
EP (6) EP2311978A1 (enExample)
JP (2) JP2006514823A (enExample)
KR (1) KR20050058407A (enExample)
CN (2) CN101044247B (enExample)
AT (1) ATE519862T1 (enExample)
AU (1) AU2003265556A1 (enExample)
CA (1) CA2496272A1 (enExample)
WO (1) WO2004018999A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009522551A (ja) * 2005-12-30 2009-06-11 ベンタナ・メデイカル・システムズ・インコーポレーテツド 子宮頸部異形成および子宮頸癌におけるＮａ＋、Ｋ＋−ＡＴＰアーゼの発現
JP2010203988A (ja) * 2009-03-05 2010-09-16 Yamaguchi Univ 子宮頸癌の検出方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
KR20050058407A (ko) * 2002-08-20 2005-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
AU2003278112A1 (en) * 2002-10-18 2004-05-04 Silence Therapeutics Ag Factor involved in metastasis and uses thereof
DE602005009702D1 (de) * 2004-07-16 2008-10-23 Oncomethylome Sciences S A Esr1 und gebärmutterhalskrebs
KR100939274B1 (ko) 2004-08-16 2010-01-29 쿠아크 파마수티칼스 인코퍼레이티드 알티피801 억제제의 치료적 용도
JP2009508493A (ja) 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
AT502722B8 (de) * 2005-10-31 2009-08-15 Bmt Medizinische Forschung Und Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc THERAPEUTIC USES OF RTP801L INHIBITORS
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR20120034593A (ko) * 2009-03-09 2012-04-12 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 위암 진단용 단백질 마커의 동정
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
CN102372773B (zh) 2010-08-11 2013-06-05 中国科学院生物物理研究所 人膀胱癌肿瘤标志物及其抗体和应用
MX347611B (es) 2011-06-19 2017-05-04 Abogen Inc Dispositivos, soluciones y metodos para recoleccion de muestras.
US9804160B2 (en) 2011-09-28 2017-10-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein-protein interaction as biomarkers
JP5876359B2 (ja) * 2012-03-30 2016-03-02 シスメックス株式会社 癌化情報提供方法および癌化情報提供装置
US20160187341A1 (en) * 2013-08-08 2016-06-30 The Research Foundation For The State University Of New York Keratins as biomarkers for cervical cancer and survival
CN114965989A (zh) 2015-02-09 2022-08-30 Dna吉诺特克股份有限公司 用于采集相关应用、分析和诊断的样本的设备、溶液和方法
SG11201708360TA (en) * 2015-04-13 2017-11-29 Aduro Biotech Inc Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
HK1250731A1 (zh) 2015-04-13 2019-01-11 艾杜罗生物科技公司 用於治疗癌症的免疫原性融合蛋白
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
CN109198732A (zh) * 2018-08-20 2019-01-15 苏州晞光生物科技有限公司 一种智能化可穿戴检测人体分泌物的服装及测试方法
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins
WO2002008419A1 (en) * 2000-07-26 2002-01-31 National Cancer Centre Of Singapore Pte Ltd Molecular markers
WO2002007828A1 (en) * 2000-07-18 2002-01-31 Collinson Jones Anthony A golf puttercover with an accessories attachment device
WO2003076631A2 (de) * 2002-03-13 2003-09-18 Ganymed Pharmaceuticals Ag Differentiell in tumoren exprimierte genprodukte und deren verwendung
JP2004509629A (ja) * 2000-09-19 2004-04-02 ホワイトヘッド　インスチチュート　フォアー　バイオメディカル　リサーチ 腫瘍に対する遺伝子マーカー

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992012236A1 (en) * 1991-01-11 1992-07-23 The Regents Of The University Of California A NOVEL INTEGRIN β SUBUNIT AND USES THEREOF
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6033862A (en) 1996-10-30 2000-03-07 Tokuyama Corporation Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications
EP1019503A4 (en) * 1997-08-06 2003-04-23 Millennium Pharm Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES TANGO-71, TANGO-73, TANGO-74, TANGO-76 AND TANGO-83
CN1282422A (zh) * 1997-10-21 2001-01-31 癌症研究行动技术有限公司 对细胞生长异常的测定
AU750296B2 (en) * 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
KR20050058407A (ko) * 2002-08-20 2005-06-16 밀레니엄 파머슈티컬스 인코퍼레이티드 자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
KR20080075045A (ko) * 2004-03-24 2008-08-13 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins
WO2002007828A1 (en) * 2000-07-18 2002-01-31 Collinson Jones Anthony A golf puttercover with an accessories attachment device
WO2002008419A1 (en) * 2000-07-26 2002-01-31 National Cancer Centre Of Singapore Pte Ltd Molecular markers
JP2004509629A (ja) * 2000-09-19 2004-04-02 ホワイトヘッド　インスチチュート　フォアー　バイオメディカル　リサーチ 腫瘍に対する遺伝子マーカー
WO2003076631A2 (de) * 2002-03-13 2003-09-18 Ganymed Pharmaceuticals Ag Differentiell in tumoren exprimierte genprodukte und deren verwendung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009522551A (ja) * 2005-12-30 2009-06-11 ベンタナ・メデイカル・システムズ・インコーポレーテツド 子宮頸部異形成および子宮頸癌におけるＮａ＋、Ｋ＋−ＡＴＰアーゼの発現
JP2010203988A (ja) * 2009-03-05 2010-09-16 Yamaguchi Univ 子宮頸癌の検出方法

Also Published As

Publication number Publication date
US20120264625A1 (en) 2012-10-18
CN102220423A (zh) 2011-10-19
AU2003265556A8 (en) 2004-03-11
WO2004018999A3 (en) 2005-06-30
EP1565581A2 (en) 2005-08-24
EP1565581B1 (en) 2011-08-10
ATE519862T1 (de) 2011-08-15
KR20050058407A (ko) 2005-06-16
US20080286781A1 (en) 2008-11-20
EP2314716A1 (en) 2011-04-27
CN101044247B (zh) 2011-06-22
AU2003265556A1 (en) 2004-03-11
CN101044247A (zh) 2007-09-26
EP1565581A4 (en) 2008-01-02
US20050037010A1 (en) 2005-02-17
EP2311980A1 (en) 2011-04-20
EP2311979A1 (en) 2011-04-20
CA2496272A1 (en) 2004-03-04
WO2004018999A2 (en) 2004-03-04
EP2311978A1 (en) 2011-04-20
JP2011036247A (ja) 2011-02-24
US7361511B2 (en) 2008-04-22
EP2305836A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
EP1565581B1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US8062892B2 (en) Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US20100075325A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20050214831A1 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7799518B2 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20130102482A1 (en) Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
WO2003004989A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2012024089A (ja) ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
HK1131822A (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091124

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100816

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101022

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120913